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ABSTRACT
Fanconi anemia (FA) is a disorder of genomic instability characterized by progressive bone marrow
failure (BMF), developmental abnormalities, and an increased susceptibility to cancer. Although var-
ious consequences inhematopoietic stem/progenitor cells havebeenattributed to FA-BMF, thequest
to identify the initial pathological event is still ongoing. To address this issue, we established induced
pluripotent stem cells (iPSCs) from fibroblasts of six patients with FA and FANCAmutations. An im-
proved reprogramming method yielded iPSC-like colonies from all patients, and iPSC clones were
propagated from two patients. Quantitative evaluation of the differentiation ability demonstrated
that the differentiation propensity toward the hematopoietic and endothelial lineages is already de-
fective in early hemoangiogenic progenitors. The expression levels of critical transcription factors
were significantly downregulated in these progenitors. These data indicate that the hematopoietic
consequences in FA patients originate from the early hematopoietic stage and highlight the
potential usefulness of iPSC technology for elucidating the pathogenesis of FA-BMF. STEM CELLS
TRANSLATIONAL MEDICINE 2015;4:333–338
INTRODUCTION
Fanconi anemia (FA) is a disorder of genomic
instability characterized by progressive bone
marrow failure (BMF), developmental abnormal-
ities, and an increased susceptibility to cancer
[1–3]. The responsible genes form a common DNA
repair network referred to as the FA pathway
[4]. The FA pathway has been considered to be in-
volved in repair of DNA interstrand cross-links
(ICLs) [1–4]. The FA pathway is activated by ICL
damage, leading to themonoubiquitinationof Fan-
conianemia, complementationgroupD2(FANCD2)
and Fanconi anemia, complementation group I
(FANCI) proteins (ID complex) by FA core E3 li-
gase complex. The monoubiquitinated ID com-
plex is then loaded on damaged chromatin and
mediates homologous recombination and trans-
lesion synthesis. Althoughaccelerated apoptosis
and cell cycle arrest in hematopoietic stem/
progenitor cells have been associated with BMF
in patients with FA [5], precisely how and when
the initial event that causes this consequence
occurs have been unclear. Recent reports have
indicated that the fate of hematopoietic progeni-
tors has already been determined during fetal
liver hematopoiesis both in humans and inmouse
models of FA [5, 6]. However, tracing the earlier
developmental events to capture the initial event
is both technically and ethically impossible at
present in humans.
Induced pluripotent stem cells (iPSCs) estab-
lished from patients with FA may be useful to ad-
dress these issues because, in combination with
a proper hematopoietic differentiation system,
iPSCs can enable evaluation of the human devel-
opmental stages [7, 8]. In this study, we estab-
lished iPSCs from patients with FA and found
that their differentiation propensity toward the
hematopoietic lineage was already defective in
the early hemoangiogenic progenitor stage. This
report shows the possibility that the hematopoi-
etic consequences in patients with FA originate at
the earliest hematopoietic stage.
MATERIALS AND METHODS
Detailedmethods are included in the supplemental
online data.
Study Ethics
This study was approved by the ethics commit-
tees of Kyoto University and Tokai University,
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Figure 1. Establishment of FA-iPSC lines frompatientswith FA andmutations in FANCA. CiRA00115 is a control iPSC line. (A): The experimental
scheme. (B): Themorphology and immunostaining of pluripotent markers of FA-iPSCs and teratoma formation by the FA-iPSC lines (ectoderm:
neural rosette; mesoderm: cartilage; endoderm: gut-like structure). Scale bars indicate 100 mm. (C): The results of karyotype analysis of fibro-
blasts and iPSCs from FA patients. The karyotypes of the fibroblasts were 46XX and 46XY for FA02 and FA07, respectively. The karyotype of
FA-iPSCs from FA02 was summarized as 46, XX, t(12;18)(p11.2;p11.2) [20 cells]. The karyotypes of FA-iPSCs from FA07 were as follows: for
FA07-2, 46, XY, add(1)(q32) [14 cells] and 46, XY [6 cells]; for FA07-3, 42-46, XY, add(8)(q24.1),add(11)(q23),del(11)(q23),add(18)(q21) [17 cells]
and 42-46, XY, add(8)(q24.1),add(9)(q34),add(21)(p11.2) [3 cells]; for FA07-4, 45-46, XY, add(8)(q24.1),add(9)(q34),add(21)(p11.2) [20 cells].
Twenty metaphases were analyzed for each sample. Abbreviations: cFA, FANCA-complemented FA-iPSC clone; FA, Fanconi anemia; HAPC,
hemoangiogenic progenitor cell; iPSC, induced pluripotent stem cell.
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patients’ guardians in accordance with the Declaration of
Helsinki.
Establishment and Differentiation of iPSCs From
Patients With FA
Fibroblasts obtained from the six patients with FA (detail
shown in supplemental online Table 1) were reprogrammed
with episomal vectors encoding OCT3/4, SOX2, KLF4, LIN28,
and L-MYC and a short hairpin RNA (shRNA) encoding a p53
knockdown sequence, as described previously [9]. Plasmids
were kindly provided by Dr. Keisuke Okita (Kyoto University).
For hematopoietic differentiation, a two-dimensional hemato-
poietic differentiation system was used, as described previ-
ously [10, 11].
RESULTS AND DISCUSSION
We tried to reprogram fibroblasts obtained from six patientswith
FA and mutations in complementation group A (FA-A; patients
with mutations in the Fanconi anemia, complementation group
A [FANCA] gene) (supplemental online Table 1) by introducing
the previously described reprogramming factors (OCT3/4,
SOX2, KLF4, c-MYC) with retroviral [7] or Sendai viral vectors
[12] under hypoxic conditions (5% O2). Consistent with the previ-
ous reports [13], no iPSC-like colonies emerged. Recently, several
groups reported that using a combination of highly efficient
methods, including improved vectors such as a polycistronic
OSKM cassette or additional reprograming factors under hypoxic
culture conditions, could overcome the reprogramming resis-
tance of FA cells [14–16]. Hence, we tried to establish FA
patient-specific iPSCs by using episomal vectors encoding
OCT3/4, SOX2, KLF4, LMYC, LIN28, and an shRNA-mediated p53
knockdown construct [9] under hypoxic conditions (5% O2). As
a result, iPSC-like colonies arose fromall FA patient-derived fibro-
blasts (supplemental online Table 1); however, we could pick up
and maintain only the TKFA02 and TKFA07 patient-derived iPSC
(FA-iPSC) lines. The colonies arising from the TKFA03, FA44,
FA45, and FA46 patients could not be picked up and propagated.
Figure 2. Validation of FA pathway in FA-iPSC lines. KhES1 is a control embryonic stem cell line, and 409B2 and 253G4 are control iPSC lines. (A):
Immunoblotting for FANCA. (B): The formation of FANCD2 foci (green) in the nuclei (stainedwith DAPI; blue) ofmitomycin C-treated FA-iPSCs (FA07)
and cFA-iPSCs (cFA07) (left). The percentage of nuclei positive for FANCD2 foci (right). (C): Representative immunofluorescent staining (upper) and
quantification (lower) of the nuclear foci of phosphorylatedH2AX. The y-axis in the graph indicates the percentage of cells with three ormore nuclear
phosphorylated H2AX foci. All data are presented as mean6 SD and are representative of three independent experiments. All p values were deter-
minedby Student’s t test.p,p, .05;pp,p, .01 (n=3). Scale bars indicate 10mm.Abbreviations: cFA, FANCA-complemented FA-iPSC clone;DAPI, 49,
6-diamidino-2-phenylindole; FA, Faconi anemia; iPSC, induced pluripotent stem cell; MMC, mitomycin C; WT, wild type.
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Consequently, we selected one and three FA-iPSC lines of the
TKFA02 and TKFA07 cells, respectively (Fig. 1A).
The FA-iPSC lines showed human pluripotent cell-like mor-
phology, expressed pluripotent markers, and differentiated into
three germ layers in the teratoma formation assay (Fig. 1B).
A short tandem repeated analysis confirmed that the patient
identity was conserved throughout the reprogramming pro-
cess (supplemental online Fig. 1). The FA-iPSC lines had
residual transgene expressions, as reported previously [16] (sup-
plemental online Fig. 2A). Consistent with this, these FA-iPSC
clones, including their complemented counterparts (discussed
below), showed reduced p53 expression (supplemental online
Fig. 2B). Although the fibroblasts from both patients had normal
karyotypes, both FA-iPSC lines had aberrant karyotypes (Fig. 1C),
which is compatiblewith a previous report [16] and indicates that
the FA pathway has an important role in determining chromo-
somal stability through reprogramming events. Collectively,
by combining the reprogramming factors with modulation of
the p53 pathway, we were able to develop a robust reprogram-
ming strategy that enabled us to establish iPSC-like colonies
from FA patient-derived somatic cells.
To establish isogenic FANCA-complemented clones, we intro-
duced exogenouswild-type FANCA cDNA into each clone (Fig. 2A;
supplemental online Fig. 3). Mitomycin C-induced FANCD2 foci
formation was restored in these FANCA-complemented FA-iPSC
clones (designated as cFA-iPSCs) (Fig. 2B). During maintenance
of the iPSCs, the FA-iPSCs showed an increased DNA double-
strand break rate, as evaluated by the frequency of nuclear foci
of phosphorylated H2AX compared with the complemented
counterparts (Fig. 2C), but the distribution of the cells in the dif-
ferent phases of the cell cycle was not significantly different
(supplemental online Fig. 4). Consequently, the complementa-
tion of the FA pathway recovers the in vitro phenotype of
FA-iPSCs.
To determine whether the hematopoietic differentiation is
affected by disruption of the FA pathway, we next differentiated
Figure 3. The defective differentiation propensity in Fanconi anemia induced pluripotent stem cell-derived hemoangiogenic progenitors.
KhES1 and 409B2 are control embryonic and induced pluripotent stem cell lines, respectively. (A): A schematic diagram of hematopoietic dif-
ferentiation. (B–E): The number of differentiated cells derived from 5,000 sorted KDR1CD341 cells. (B): CD341CD451 hematopoietic progen-
itors. (C):CD331CD451myeloid cells. (D):CD452CD235a1erythroid cells. (E):CD311CD341endothelial cells. All data arepresented asmean6
SD and are representative of three independent experiments. All p values were determined byWilcoxon rank sum test. p, p, .05; pp, p, .01;
ppp, p, .001 (n = 3). Abbreviations:a-MEM, alphaMinimum EssentialMedium; bFGF, basic fibroblast growth factor; EPO, erythropoietin; IL-3,
interleukin 3; NS, not significant; SCF, stem cell factor; TPO, thyroid peroxidase; VEGF, vascular endothelial growth factor.
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the FA-iPSC lines into hematopoietic progenitor cells through the
previously reported serum- and feeder-free monolayer culture
system [10, 11]. Under this protocol, the progenitor cells commit-
ted to the hematopoietic lineage are obtained as KDR1CD341
early hemoangiogenic progenitor cells (HAPCs), which give rise
to both endothelial and hematopoietic cells. To evaluate the
differentiation propensity of HAPCs quantitatively, we sorted
the KDR1CD341 HAPCs on day 6 and cultured them on OP9
feeder cells with lineage-specific cytokine cocktails (Fig. 3A;
supplemental online Fig. 5). TheFA-iPSC lines showedasignificant
reduction of CD341CD451 hematopoietic precursors compared
with cFA-iPSC lines (Fig. 3B). Subsequently, the myeloid and ery-
throid lineage hematopoietic cells were significantly reduced
(Fig. 3C, 3D). The number of CD311 endothelial cells from FA-
iPSC-derived HAPCs (FA-HAPCs) was also reduced comparedwith
that in the cFA-iPSC lines (Fig. 3E). The distribution of the cell cycle
in FA-iPSC-derived KDR1CD341HAPCswas comparable to that of
the complemented counterparts (supplemental online Fig. 6).
We also confirmed that KDR1CD341 HAPCs were not apoptotic
(supplemental online Fig. 7). Although the expression level of
p53 reduced and varied among the FA- or cFA-iPSC lines
(supplemental online Fig. 2B), the ability of these cells to undergo
hematopoietic differentiation was dependent on the FANCA sta-
tus but not on the p53 level, indicating that, at least in this study,
the expression level of p53 has no obvious impact on the dif-
ferentiation propensity of HAPCs. Taken together, these findings
indicate that FA-HAPCs showed a defective propensity to differ-
entiate toward both hematopoietic and endothelial lineages.
To further elucidate the mechanism underlying the defective
hematopoietic differentiation, we next quantified the expression
levels of critical transcription factors requird for hematopoietic
differentiation in HAPCs [17–20]. HAPCs from FA-iPSC lines
showed significant downregulation of these transcription factors
(Fig. 4A–4D), indicating that the FA pathway might be involved in
maintaining the transcriptional network critical for determining
the differentiation propensity of HAPCs. We also compared the
global expression profiles of HAPCs from FA- and cFA-iPSCs
(supplemental online Fig. 8A, 8B). We identified that 227 genes
were significantly upregulated and 396 genes were significantly
downregulated in FA-HAPCs (supplemental online Fig. 8C;
supplemental online Table 2). A gene ontology enrichment anal-
ysis revealed that genes associated with mesodermal differenti-
ation, vascular formation, and hematopoiesis were extensively
downregulated in FA-HAPCs (supplemental online Fig. 8D).
CONCLUSION
In summary, we successfully established FA-iPSCs from FA-A
patients. We found that an early pathological phenotype was
detected in HAPCs as a defective differentiation propensity into
both hematopoietic and endothelial lineages. Interestingly, dur-
inghematopoiesis, theexpressionof FANCAandFANCCwere spe-
cifically upregulated in KDR1CD341 HAPCs (supplemental online
Fig. 9), indicating the stage-specific requirement of these genes in
HAPCs. Because the expression of hematopoietic and angiogenic
genes was affected, FANCA may have an important role in regu-
lating these genes in FA-HAPCs. Conducting a comprehensive
analysis of patient-derived affected progenitors is not feasible
without iPSC technology, which provides an unprecedented op-
portunity to gain further insight into the pathogenesis of BMF
in patients with FA.
Figure 4. FANCA-deficient hemoangiogenic progenitor cells show thedecreasedexpression of hematopoieticmarker genes. (A–D):The results
of thequantitative polymerase chain reaction analysis for hematopoieticmarker genes in KDR1CD341hemoangiogenic progenitors (day 6). The
relative gene expression (y-axis) was calculated relative to the expression in corresponding cFA induced pluripotent stem cells after normal-
ization to the expression of glyceraldehyde-3-phosphate dehydrogenase. All data are presented as mean6 SD and are representative of three
independent experiments. All p values were determined by Student’s t test. p, p, .05; pp, p, .01; ppp, p, .001 (n = 3). Abbreviation: cFA,
FANCA-complemented Fanconi anemia induced pluripotent stem cell clone.
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